Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer

Join Sam Chang, MD, and Lan Gellert, MD, PhD, as they present their multidisciplinary expertise on a range of cases pertaining to Kidney Cancer.

An improved understanding of the biology of renal cell carcinoma (RCC) has led to the development of new targeted therapies. To date, seven such agents have been approved by the FDA for the treatment of advanced RCC: sunitinib malate, sorafenib tosylate, temsirolimus, everolimus, bevacizumab in combination with interferon, pazopanib, and axitinib. While expansion of knowledge and treatment options has improved patient care, it has presented numerous clinical challenges. The largest challenge lies in deciding upon the best first-line treatment for a given patient as well as effectively managing toxicities and adverse effects. In addition, nearly every patient with metastatic RCC requires second, third, and subsequent lines of therapy. Therefore, the challenge also lies in selecting the best sequence of treatment to provide maximum benefit to the patient.  Advances have been made in supportive care treatment as well. New drugs with novel mechanism of action (e.g., denosumab) are available for treatment of metastatic bone disease. New targeted therapies, such as tivozonib, among others, are currently under investigation in various clinical trials. Knowledge of the ongoing and upcoming trials is critical to counsel appropriate patients with RCC and provide optimal care.

An improved understanding of the biology of RCC has led to the development of new targeted therapies. To date, seven such agents have been approved by the FDA for the treatment of advanced RCC. Patients will be exposed to multiple agents using a continuum of care paradigm.  Helping them to develop realistic expectations is a critical part of caring for these patients.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies for kidney cancer in the treatment of patients
  • Describe the multidisciplinary aspects of patient management for kidney cancer
  • Identify the key characteristics for kidney cancer that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Daiichi Sankyo, Inc.
  • Genentech
  • Novartis Pharmaceuticals Corporation
  • Takeda Oncology
  • Teva Pharmaceuticals

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This activity is supported by a grant from Onyx Pharmaceuticals.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.80 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
03/10/2014
Course expires: 
03/10/2015
Cost:
$0.00

Sam S. Chang, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN

Lan Gellert, MD, PhD
Vanderbilt-Ingram Cancer Center
Nashville, TN

Available Credit

  • 0.75 Participation
  • 0.80 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Accreditation Period

Course opens: 
03/10/2014
Course expires: 
03/10/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • For Windows: JavaScript and cookies enabled, Active X enabled and unblocked for Microsoft Internet Explorer, Java 6.0 or above
  • For Mac: JavaScript and cookies enabled, Plug-ins enabled in Safari, Java 6.0 or above
  • Adobe Reader or other PDF reader software for certificate viewing/printing